TIP60 is required for tumorigenesis in non‐small cell lung cancer
Cancer Science · 2023
DOI: 10.1111/cas.15785 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Daisuke Shibahara und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIEHS NIH HHS, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Histone modifications play crucial roles in transcriptional activation, and aberrant epigenetic changes are associated with oncogenesis. Lysine (K) acetyltransferases 5 (TIP60, also known as KAT5) is reportedly implicated in cancer development and maintenance, although its function in lung cancer remains controversial. Here we demonstrate that TIP60 knockdown in non‐small cell lung cancer cell lines decreased tumor cell growth, migration, and invasion. Furthermore, analysis of a mouse lung cancer model with lung‐specific conditional Tip60 knockout revealed suppressed tumor formation relative to controls, but no apparent effects on normal lung homeostasis. RNA‐seq and ChIP‐seq analyses of inducible TIP60 knockdown H1975 cells relative to controls revealed transglutaminase enzyme (TGM5) as downstream of TIP60. Investigation of a connectivity map database identified several candidate compounds that decrease TIP60 mRNA, one that suppressed tumor growth in cell culture and in vivo . In addition, TH1834, a TIP60 acetyltransferase inhibitor, showed comparable antitumor effects in cell culture and in vivo . Taken together, suppression of TIP60 activity shows tumor‐specific efficacy against lung cancer, with no overt effect on normal tissues. Our work suggests that targeting TIP60 could be a promising approach to treating lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pathology, University of California San Francisco, San Francisco, California, USA.
- Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, South Korea.
- Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Department of Genetics and Genomic Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York, USA.
- Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Susumu S Kobayashi
Förderung
- NIEHS NIH HHS
- NCI NIH HHS
- NIH HHS
- National Cancer Institute
Zitieren
APA
Shibahara, D., Akanuma, N., Kobayashi, I. S., Heo, E., Ando, M., Fujii, M., Jiang, F., Prin, P. N., Pan, G., Wong, K. K., Costa, D. B., Bararia, D., Tenen, D. G., Watanabe, H., & Kobayashi, S. S. (2023). TIP60 is required for tumorigenesis in non‐small cell lung cancer. Cancer Science. https://doi.org/10.1111/cas.15785
Vancouver
Shibahara D, Akanuma N, Kobayashi IS, Heo E, Ando M, Fujii M, et al. TIP60 is required for tumorigenesis in non‐small cell lung cancer. Cancer Science. 2023. doi:10.1111/cas.15785
BibTeX
@article{Shibahara2023,
author = {Shibahara, Daisuke and Akanuma, Naoki and Kobayashi, Ikei S and Heo, Eunyoung and Ando, Mariko and Fujii, Masanori and Jiang, Feng and Prin, P Nicholas and Pan, Gilbert and Wong, Kwok-Kin and Costa, Daniel B and Bararia, Deepak and Tenen, Daniel G and Watanabe, Hideo and Kobayashi, Susumu S},
title = {TIP60 is required for tumorigenesis in non‐small cell lung cancer},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15785}
}
EUVIMED